Tonix Pharmaceuticals Announces First Patient Dosed In Phase 2 Oasis Study Of TNX-102 SL For Reduction Of Acute Stress Reaction
May 21 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O:
TONIX PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 OASIS STUDY OF TNX-102 SL FOR REDUCTION OF ACUTE STRESS REACTION
TONIX PHARMACEUTICALS HOLDING CORP - TOPLINE RESULTS EXPECTED IN SECOND HALF OF 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.